Thyroid cancer patients may spend less time in discomfort with simple phone calls
NCT ID NCT01298323
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase 3 trial tested whether a patient outreach program—regular phone calls every two weeks—could help people with advanced medullary thyroid cancer spend less time experiencing moderate-to-severe side effects from the drug vandetanib. The study enrolled 205 adults and compared those who received the outreach calls to those who did not. The goal was to see if early detection and management of side effects could improve the treatment experience.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vandetanib
What this could lead to
If successful, this outreach program could help patients on vandetanib spend less time dealing with bothersome side effects, improving their daily quality of life.
What could go wrong
This study focuses on managing side effects, not on curing cancer. The outreach program may not significantly reduce side effects, and results may not apply to other cancer types or treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEDULLARY THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Faculdade de Medicina de Ribeirao Preto - USP Site Number : 702
Ribeirão Preto, São Paulo, 14048-900, Brazil
-
Hospital De Clinicas De Porto Alegre Site Number : 701
Porto Alegre, Rio Grande do Sul, 90035-003, Brazil
-
Investigational Site Number 1001
London, N6A 4L6, Canada
-
Investigational Site Number 1002
Sherbrooke, J1H 5N4, Canada
-
Investigational Site Number 1003
Toronto, M5G2M9, Canada
-
Investigational Site Number 1301
Beijing, 100021, China
-
Investigational Site Number 1302
Shanghai, China
-
Investigational Site Number 1901
Prague, 15006, Czechia
-
Investigational Site Number 2001
Odense C, 5000, Denmark
-
Investigational Site Number 2201
Helsinki, FI-00029, Finland
-
Investigational Site Number 2601
Würzburg, 97080, Germany
-
Investigational Site Number 2602
Essen, 45122, Germany
-
Investigational Site Number 2603
Halle, 06120, Germany
-
Investigational Site Number 2801
Sutton, SM25PT, United Kingdom
-
Investigational Site Number 2802
Glasgow, G120YN, United Kingdom
-
Investigational Site Number 3001
Athens, 11528, Greece
-
Investigational Site Number 301
St Leonards, 2065, Australia
-
Investigational Site Number 3501
Mumbai, 400012, India
-
Investigational Site Number 3502
Vellore, 632004, India
-
Investigational Site Number 4001
Jerusalem, 91120, Israel
-
Investigational Site Number 401
Vienna, 1901, Austria
-
Investigational Site Number 4101
Pisa, 56124, Italy
-
Investigational Site Number 4102
Roma, 00161, Italy
-
Investigational Site Number 4104
Naples, Italy
-
Investigational Site Number 501
Brussels, 1000, Belgium
-
Investigational Site Number 5702
Poznan, 60-355, Poland
-
Investigational Site Number 5703
Warsaw, 02-781, Poland
-
Investigational Site Number 6001
Seoul, South Korea
-
Investigational Site Number 6201
Moscow, 115478, Russia
-
Investigational Site Number 6202
Obninsk, 249036, Russia
-
Investigational Site Number 6203
Saint Petersburg, 197022, Russia
-
Investigational Site Number 6204
Moscow, 125284, Russia
-
Investigational Site Number 701
Porto Alegre, 90035-003, Brazil
-
Investigational Site Number 702
Ribeirão Preto, 14048-900, Brazil
-
Investigational Site Number 7201
Uppsala, 75185, Sweden
-
Investigational Site Number 901
Sofia, 1527, Bulgaria
-
Investigational Site Number : 1001
London, Ontario, N6A 4L6, Canada
-
Investigational Site Number : 1002
Sherbrooke, Quebec, J1H 5N4, Canada
-
Investigational Site Number : 1003
Toronto, Ontario, M5G2M9, Canada
-
Investigational Site Number : 1301
Beijing, 100021, China
-
Investigational Site Number : 1302
Shanghai, China
-
Investigational Site Number : 1901
Prague, 15006, Czechia
-
Investigational Site Number : 2001
Odense C, 5000, Denmark
-
Investigational Site Number : 2201
Helsinki, FI-00029, Finland
-
Investigational Site Number : 2601
Würzburg, 97080, Germany
-
Investigational Site Number : 2602
Essen, 45122, Germany
-
Investigational Site Number : 2603
Halle, 06120, Germany
-
Investigational Site Number : 2801
Sutton, Surrey, SM25PT, United Kingdom
-
Investigational Site Number : 2802
Glasgow, G120YN, United Kingdom
-
Investigational Site Number : 3001
Athens, 11528, Greece
-
Investigational Site Number : 301
St Leonards, New South Wales, 2065, Australia
-
Investigational Site Number : 3501
Mumbai, 400012, India
-
Investigational Site Number : 3502
Vellore, 632004, India
-
Investigational Site Number : 4001
Jerusalem, 91120, Israel
-
Investigational Site Number : 401
Vienna, 1901, Austria
-
Investigational Site Number : 4101
Pisa, 56124, Italy
-
Investigational Site Number : 4102
Roma, 00161, Italy
-
Investigational Site Number : 4104
Naples, Italy
-
Investigational Site Number : 501
Anderlecht, 1070, Belgium
-
Investigational Site Number : 5702
Poznan, Greater Poland Voivodeship, 60-355, Poland
-
Investigational Site Number : 5703
Warsaw, Masovian Voivodeship, 02-781, Poland
-
Investigational Site Number : 6001
Seoul, 03080, South Korea
-
Investigational Site Number : 6201
Moscow, 115478, Russia
-
Investigational Site Number : 6202
Obninsk, 249036, Russia
-
Investigational Site Number : 7201
Uppsala, 75185, Sweden
-
Investigational Site Number : 901
Sofia, 1527, Bulgaria